BioCentury
ARTICLE | Financial News

DRI acquires royalty rights to Ampyra for $42M

August 13, 2014 12:24 AM UTC

DRI Capital's private equity fund Drug Royalty III acquired worldwide royalty rights to multiple sclerosis drug Ampyra dalfampridine from Rush University Medical Center for about $42 million. In 2013, DRI Capital closed the fund at $1.5 billion (see BioCentury Extra, Sept. 9, 2013). ...